Therapeutic implications and role of serum sphingolipids on psoriasis severity after narrow band ultraviolet B treatment: A cross sectional controlled study

2020 ◽  
Vol 33 (6) ◽  
Author(s):  
Hesham A. Nada ◽  
Mohamed M. Elshabrawy ◽  
Nader I. Ismail ◽  
Eman T. Hassan ◽  
Mohammad Jafferany ◽  
...  
Keyword(s):  
Narrow Band ◽  
Ultraviolet B ◽  
Controlled Study ◽  
Cross Sectional ◽  
Therapeutic Implications ◽  
Psoriasis Severity

Therapeutic implications of narrow band ultraviolet B on psoriasis severity and serum levels of acute phase reactants

2020 ◽  
Vol 33 (6) ◽  
Author(s):  
Hesham A. Nada ◽  
Mohamed M. Elshabrawy ◽  
Doaa M. Aly ◽  
Mohammad Jafferany ◽  
Mohamed L. Elsaie
Keyword(s):  
Acute Phase ◽  
Narrow Band ◽  
Serum Levels ◽  
Ultraviolet B ◽  
Acute Phase Reactants ◽  
Therapeutic Implications ◽  
Psoriasis Severity

scholarly journals Role of adjuvant narrow band ultraviolet B phototherapy in the treatment of chronic urticaria

2019 ◽  
Vol 64 (3) ◽  
pp. 250
Author(s):  
Iffat Hassan ◽  
Gousia Sheikh ◽  
Insha Latif ◽  
KouserSideeq Lone ◽  
Yasmeen Jabeen ◽  
...  
Keyword(s):  
Chronic Urticaria ◽  
Narrow Band ◽  
Ultraviolet B

Therapeutic implications of C‐reactive protein and uric acid in patients with psoriasis before and after narrow band ultraviolet B therapy

2020 ◽  
Vol 33 (6) ◽  
Author(s):  
Mamoun Shalaby ◽  
Ahmad Elshahid ◽  
Ahmed Metwaly ◽  
Ayda Ibrahim ◽  
Mohammad Jafferany ◽  
...  
Keyword(s):  
Uric Acid ◽  
Narrow Band ◽  
Ultraviolet B ◽  
C Reactive Protein ◽  
Therapeutic Implications ◽  
Reactive Protein ◽  
Before And After

Sitagliptin and Narrow-Band Ultraviolet-B for Moderate Psoriasis (DINUP): A Randomised Controlled Clinical Trial

Dermatology ◽  
2021 ◽  
pp. 1-8
Author(s):  
Maeve Lynch ◽  
Anna Malara ◽  
Irene Timoney ◽  
Sebastian Vencken ◽  
Tomas Ahern ◽  
...  
Keyword(s):  
Narrow Band ◽  
Disease Risk ◽  
Cardiovascular Disease Risk ◽  
Depression Scale ◽  
Ultraviolet B ◽  
Controlled Clinical Trial ◽  
Significant Difference ◽  
Randomised Controlled ◽  
Uvb Phototherapy ◽  
Psoriasis Severity

<b><i>Background:</i></b> Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor licensed for the treatment of type 2 diabetes mellitus (T2DM), has been reported to improve psoriasis. <b><i>Objective:</i></b> We compared the effects of sitagliptin treatment, a DPP-4 inhibitor, in combination with narrow-band ultraviolet-B (NB-UVB) phototherapy compared to NB-UVB alone on psoriasis severity, quality of life, cardiovascular disease risk factors and immune parameters in people with moderate psoriasis without T2DM. <b><i>Methods:</i></b> In this 39-week, single-centre, randomised controlled trial, people were allocated randomly to receive sitagliptin for 24 weeks with NB-UVB or NB-UVB alone. The primary endpoint was the change in Psoriasis Area and Severity Index (PASI) from baseline to 24 weeks. We estimated that 120 participants would be needed to have 80% power to find a significant difference between the groups. <b><i>Results:</i></b> A total of 118 patients were randomised. The median (IQR) baseline PASI was 8.8 (7.5–11.6). At 24 weeks, the mean difference from baseline in PASI (–1.0 [95% CI –2.0 to 0.0]) was significantly larger in the sitagliptin/NB-UVB arm than in the NB-UVB-alone arm (<i>p</i> = 0.044). There were significant differences in the change in Hospital Anxiety and Depression Scale (–2.5 [95% CI –4.0 to –1.0]; <i>p</i> = 0.002) and EuroQol 5-item questionnaire (0.1 [95% CI 0.0–0.1]; <i>p</i> = 0.036) values from baseline to 24 weeks between the sitagliptin/NB-UVB and the NB-UVB-alone arm. There were no treatment-related serious adverse events. <b><i>Conclusion:</i></b> Sitagliptin therapy combined with NB-UVB phototherapy significantly improved psoriasis severity, albeit modestly, compared to NB-UVB phototherapy alone in patients with moderate psoriasis without T2DM.

Role of chemokine ligand 22 in narrow-band ultraviolet B-induced pigmentation in vitiligo: an immunohistochemical study

2019 ◽  
Vol 16 (2) ◽  
pp. 97
Author(s):  
AzzaG Antar Farag ◽  
MostafaA Hammam ◽  
DaliaR Al-Sharaky ◽  
ReemA Hassan ◽  
EmanN ElShafey ◽  
...  
Keyword(s):  
Immunohistochemical Study ◽  
Narrow Band ◽  
Ultraviolet B ◽  
Chemokine Ligand

Safe and effective use of phototherapy and photochemotherapy in the treatment of psoriasis

2020 ◽  
Vol 29 (10) ◽  
pp. 547-552
Author(s):  
Joanna Campbell
Keyword(s):  
Side Effects ◽  
Inflammatory Disease ◽  
Narrow Band ◽  
Ultraviolet B ◽  
Second Line ◽  
Skin Involvement ◽  
Ultraviolet A ◽  
History Of ◽  
Effective Use

Psoriasis is a chronic, multisystem inflammatory disease, predominantly affecting the skin and joints, which is present in 2−3% of the world's population. Narrow band ultraviolet B (NB-UVB) and Psoralen + ultraviolet A (PUVA) are recognised, effective and, in the case of UVB, economical second-line treatments for psoriasis where topical therapies fail to control the disease or are an impracticable option due to the extent of skin involvement. This article examines the history of phototherapy and photochemotherapy and looks at current phototherapy treatments used for psoriasis. It discusses side effects of treatment and regimens that can be followed to increase effectiveness of treatment and minimise risks. The role of the nurse phototherapist is also discussed.

Evaluation of High-Sensitive C Reactive Protein Serum Level in Patients with Chronic Plaque Psoriasis before and After Treatment with Narrow Band Ultraviolet B Therapy or Methotrexate Comparative Study

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Lobna Ebrahim Eldahshan ◽  
Saleh Mohammed ElShiemy ◽  
Rania Mahmoud El Husseiny ◽  
Wael Mohammed Saudy
Keyword(s):  
Serum Level ◽  
Plaque Psoriasis ◽  
Narrow Band ◽  
Ultraviolet B ◽  
C Reactive Protein ◽  
Chronic Plaque Psoriasis ◽  
Reactive Protein ◽  
Before And After ◽  
Protein Serum ◽  
Psoriasis Severity

Abstract Background Psoriasis is a chronic, recurring inflammatory disease affecting the skin, joints and nails that has a significant negative impact on the quality of life.Highly sensitive c reactive protein ( hsCRP) could be useful as biomarker for assessing the psoriasis severity(1). Objectives Assess the changes in high-sensitive C-reactive protein serum level in patients with chronic plaque psoriasis before and after treatment with narrow band ultraviolet B therapy and Methotrexate. Patients and Methods Our Prospective clinical study included 40 patients of both sex, aged 20-60 years old with psoriasis vulgaris recruited from dermatology outpatient clinic of Ain Shams University Hospital from January 2018 to December 2018. The study was approved by Ain Shams University ethical committee. Informed consents were taken from each Patient after full description of the study aims and procedures Results Both methotrexate and nb-uvb showed significant decrease in serum level hscrp ,PASI score and DLQI after 12 weeks of treatment ,although there were statistically significant lower PASI , DLQI scores and serum level hscrp after 12 weeks of treatment in methotrexate group of patient compared to nb-uvb group of patients Conclusion Highly sensitive C reactive protein(hscrp) is a promising inflammatory marker for monitoring psoriasis severity and efficacy of treatment respectively .Methotrexate treatment showed significant effect on psoriasis severity regarding lowering hscrp serum level ,PASI and DLQI in compared to Nb_UVB therapy .

Sign in / Sign up

Export Citation Format

Share Document